nach oben

Drugs

Erschienen in:

01.12.2020 | AdisInsight Report

Sofpironium Bromide: First Approval

verfasst von: Julia Paik

Erschienen in: Drugs | Ausgabe 18/2020

Einloggen, um Zugang zu erhalten

Abstract

Sofpironium bromide (ECCLOCK^® in Japan) gel is a topical anticholinergic agent developed by Bodor Laboratories and licenced to Brickell Biotech for the treatment of hyperhidrosis. The drug is designed to reduce sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. In September 2020, sofpironium bromide gel 5% received its first approval in Japan for the treatment of primary axillary hyperhidrosis (PAH). Clinical studies are currently ongoing in the USA to assess the safety and efficacy of sofpironium bromide gel 15% in PAH. This article summarizes the milestones in the development of sofpironium bromide gel leading to this first approval for the treatment of PAH.

Shargall Y, Spratt E, Zeldin RA. Hyperhidrosis: what is it and why does it occur? Thorac Surg Clin. 2008;18(2):125–32, v.

Amir M, Arish A, Weinstein Y, et al. Impairment in quality of life among patients seeking surgery for hyperhidrosis (excessive sweating): preliminary results. Isr J Psychiatry Relat Sci. 2000;37(1):25–31.PubMed

Campanati A, Penna L, Guzzo T, et al. Quality-of-life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study. Clin Ther. 2003;25(1):298–308.CrossRef

Solish N, Bertucci V, Dansereau A, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33(8):908–23.PubMed

Kaken Pharmaceutical. ECCLOCK^® gel 5% approved in Japan for the treatment of primary axillary hyperhidrosis [media release]. 25 Sep 2020. http://www.kaken.co.jp/.

Kaken Pharmaceutical. ECCLOCK gel 5%. 2020. https://pmda.go.jp. Accessed 4 Nov 2020.

Brickell Biotech. Brickell Biotech provides update on Bodor Labs complaint and funding agreement with NovaQuest [media release]. 30 Oct 2019. http://brickellbio.com.

Brickell Biotech. Brickell Biotech announces settlement of dispute with Bodor Labs and entry into equity funding agreements [media release]. 18 Feb 2020. http://brickellbio.com.

Brickell Biotech. Brickell Biotech, Inc. signs exclusive license and development agreement for BBI-4000 with Kaken Pharmaceutical Co., Ltd [media release]. 1 Apr 2015. http://brickellbio.com.

10.

Brickell Biotech. Sofpironium bromide. 2020. https://brickellbio.com/rd/pipeline/sofpironium-bromide/. Accessed 4 Nov 2020.

11.

Yokozeki H, Fujimoto T, Yorozuya T, et al. A phase 3, randomized, double-blinded, vehicle-controlled study to evaluate the safety and efficacy of topically applied sofpironium bromide gel, 5% in Japanese patients with primary axillary hyperhidrosis [abstract no. S027]. In: American Academy of Dermatology, Virtual Meeting Experience. 2020.

12.

Brickell Biotech. Brickell Biotech announces positive phase 3 pivotal study results for sofpironium bromide in Japan released by development partner, Kaken Pharmaceutical [media release]. 15 Jun 2020. http://brickellbio.com.

13.

Kirsch B, Smith S, Cohen J, et al. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: a phase II, randomized, controlled, double-blinded trial. J Am Acad Dermatol. 2020;82(6):1321–7.CrossRef

14.

Brickell Biotech. BBI-4000 (sofpironium bromide) demonstrates promising potential as a safe and effective first-line treatment for excessive underarm sweating [media release]. 7 Mar 2016. http://brickellbio.com.

15.

Brickell Biotech. Brickell Biotech reports first quarter 2020 financial results and provides corporate update [media release]. 13 May 2020. http://brickellbio.com.

16.

Brickell Biotech. Brickell Biotech reports second quarter 2020 financial results and provides corporate update [media release]. 12 Aug 2020. https://brickellbio.com/.

17.

Brickell Biotech. Brickell Biotech announces initiation of US phase 3 program evaluating sofpironium bromide gel, 15% for the treatment of primary axillary hyperhidrosis [media release]. 6 Oct 2020. https://brickellbio.com/.

18.

Brickell Biotech. Brickell Biotech reports fourth quarter and full year 2019 financial results and provides corporate update [media release]. 18 Mar 2020. http://brickellbio.com.

Titel: Sofpironium Bromide: First Approval
verfasst von: Julia Paik
Publikationsdatum: 01.12.2020
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 18/2020
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-020-01438-1

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 18/2020

Correction to: Ripretinib: First Approval

Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon

Correction to: Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer

Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia

Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review